HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- When clinicians become patients, treatment journeys help shape their approaches to care
-
- Colon cancer may be a different disease in older patients
- FDA: 32-mg dose of Zofran to be removed from market
- Radiologic surveillance for early-stage Hodgkin’s appears unnecessary
- Risk model may predict thyroid cancer in childhood cancer survivors
- Survival outcomes unchanged after second-line treatment with pemetrexed plus carboplatin
- Arsenic trioxide plus ATRA comparable to standard regimen for APL
- Black women less likely than whites to undergo sentinel lymph node biopsy
- Extended tamoxifen treatment improved survival, recurrence outcomes
-
- Higher fulvestrant dose improved survival in advanced breast cancer
- Ibrutinib associated with high response rates in patients with CLL
- Parental discussion key to improving HPV immunization rates
- Standard, high-definition colonoscopy detection rates similar in community setting
- START: Lower radiation dose shows promise at 10-year follow-up
- Twice-daily doses of apixaban reduced risk of VTE
- Younger women with breast cancer responded better to neoadjuvant chemotherapy